Evaluation of Antibody and Cytokines Responses in Intranasally and Intramuscularly Administrated BALB/C Mice With Influenza Virus-Like Particle
- PMID: 29228524
Evaluation of Antibody and Cytokines Responses in Intranasally and Intramuscularly Administrated BALB/C Mice With Influenza Virus-Like Particle
Abstract
We previously developed an influenza virus like particle with HA, M, and NA proteins using Bac-to-Bac expression system and SF9 cell line. To evaluate the immunogenicity of our construct, we assessed the humoral, cytokine induced by H1N1-VLP in BALB/c mice immunized intranasally and intramuscularly. Enzyme-linked immunosorbent assay and Relative quantitative real-time PCR were used to evaluate the antibody (IgG and IgA) and mRNA levels of IL-6, IL-4, IL-10 and IFN-g in PBMCs. Our results showed that VLP was capable of intranasal (I.N.) and intramuscular (I.M.) induction of serum IgG and IgA responses. Interestingly, I.N. route induced higher IgG and IgA titer than I.M. route, which was statistically significant. Moreover, mRNA levels of IL-6 (4.2-4.5 folds), IFN-g (5.5-5.7 folds), and the anti-inflammatory cytokine IL-10 (2.5-3 folds) and IL-4 (2.4-2.8 folds) were significantly elevated in mice immunized I.N. and I.M. with H1N1-VLP compared to the control group. Our findings indicated that a non-infectious genome-less VLP approach mimics parenteral virus with multiple viral antigens and epitopes that stimulate a diverse set of immune responses such as innate immunity, specific serum IgG antibody, cell-mediated immunity, and local antibodies.
Keywords: Cytokines; Immune responses; Influenza virus-like particle; Mucosal antibody; Vaccine.
Similar articles
-
Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23. Vaccine. 2012. PMID: 22537989
-
Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.Scand J Immunol. 2015 May;81(5):305-17. doi: 10.1111/sji.12288. Scand J Immunol. 2015. PMID: 25737202
-
Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.Arch Virol. 2017 May;162(5):1251-1260. doi: 10.1007/s00705-017-3230-7. Epub 2017 Jan 24. Arch Virol. 2017. PMID: 28120096
-
Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.Hum Vaccin Immunother. 2015;11(12):2831-8. doi: 10.1080/21645515.2015.1074363. Hum Vaccin Immunother. 2015. PMID: 26260706 Free PMC article.
-
A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).Viral Immunol. 2007 Sep;20(3):441-52. doi: 10.1089/vim.2007.0027. Viral Immunol. 2007. PMID: 17931114
Cited by
-
Association of polymorphisms in inflammatory cytokines encoding genes with severe cases of influenza A/H1N1 and B in an Iranian population.Virol J. 2019 Jun 13;16(1):79. doi: 10.1186/s12985-019-1187-8. Virol J. 2019. PMID: 31196204 Free PMC article.
-
Extracellular Vesicles in the Pathogenesis of Viral Infections in Humans.Viruses. 2020 Oct 21;12(10):1200. doi: 10.3390/v12101200. Viruses. 2020. PMID: 33096825 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous